15-19 October 2016, Vienna (Austria) hosted one of the most important and prestigious events in modern experimental and clinical gastroenterology – United European Gastroenterology Week. This conference annually gathers thousands of practitioners and world leading researchers, who during numerous thematic sessions highlight the latest achievements of modern science in the treatment of the digestive tract diseases.
Today adult stem cells were shown to be involved in the processes of reparation and carcinogenesis of the digestive system, i.e. the development of liver fibrosis. Thus, cell-molecular mechanisms may become the new target for uptodate pharmacotherapy of fibrotic, inflammatory and malignant diseases of the gastrointestinal tract. Also efficacy of hematopoietic and mesenchymal stem cells in the treatment of Crohn’s disease and ulcerative colitis was reported. Local and systemic cell therapy is supposed to be promising for the stimulation of healing of intestinal ulcers, as well as it is increasingly studied in the treatment of liver cirrhosis, liver failure, viral hepatitis.
In 2016, Ukraine at UEGW in Vienna was represented by the Institute of Cell Therapy in the person of Christina Nasadyuk, PhD, clinical immunologist, who is a scientific adviser of the Institute of Cell Therapy and head of the department of the international cooperation of the Association of cryobanks.
This year UEGW program included 2 poster presentations of Christina Nasadyuk, devoted to the evaluation of the gastroprotective properties of the newly synthesized regulatory oligopeptides. This proves the significance and high professional level of presented papers, since scientific abstracts submitted for such high level forums are exposed to precise review by several independent experts and only about a half of submitted papers are accepted to the conference program.
Today in Ukraine, clinical trials approved by the Coordination Center of Transplantation of the Ministry of Health of Ukraine, designed to study the effectiveness of the novel therapies of viral hepatitis and liver cirrhosis using cord blood stem cells, developed by the Institute of Cell Therapy, are ongoing.